Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336648 · ClinicalTrials.gov registry record · Phase 2
Preop Chemoradiation Resectable Pancreas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00336648: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00336648 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00336648, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To assess resectability rate in patients undergoing gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreas. Secondary Objectives: 1. To assess disease free survival and overall survival 2. To assess margin resection rate (R0 vs. R1) in these patients 3. To assess patterns of failure
Interventions
- DRUG Gemcitabine
- PROCEDURE Radiation Therapy
- DRUG Avastin (Bevacizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336648
The ClinicalTrials.gov registry entry for NCT00336648 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00336648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336648 about?
NCT00336648 is a clinical study titled "Preop Chemoradiation Resectable Pancreas". Primary Objective: 1\. To assess resectability rate in patients undergoing gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreas. Secondary Objectives: 1. To assess disease free survival and overall survival 2. To assess margin resect...
What is the current status of trial NCT00336648?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00336648?
The interventions under investigation include: Gemcitabine (DRUG), Radiation Therapy (PROCEDURE), Avastin (Bevacizumab) (DRUG).
Who is sponsoring clinical trial NCT00336648?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.